Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C1868
http://purl.obolibrary.org/obo/NCIT_C1868
Preferred Name

Vatalanib
Definitions
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
label
Vatalanib
prefLabel
Vatalanib
Legacy Concept Name
PTK787
in_subset
Preferred_Name
Vatalanib
Is_Value_For_GDC_Property
Chemical_Formula
C20H15ClN4
Display_Name
Vatalanib
Maps_To
Vatalanib
PDQ_Open_Trial_Search_ID
43530
Has_Target
UMLS_CUI
C0912586
FDA_UNII_Code
5DX9U76296
prefixIRI
NCIT:C1868
NCI_Drug_Dictionary_ID
43530
Contributing_Source
CTRP
FDA
subClassOf
Has_Salt_Form
code
C1868
type
ALT_DEFINITION
A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors.
NSC Number
719335
PDQ_Closed_Trial_Search_ID
43530
Semantic_Type
Organic Chemical
Pharmacologic Substance
CAS_Registry
212141-54-3
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display